变应性鼻炎患者特异性免疫治疗前后TGF-β、IL-10和IL-17的变化及和症状关系的研究

卢汉桂; 邱前辉; 卢川; 陈少华; 韩虹

doi:10.13201/j.issn.1001-1781.2012.02.008

变应性鼻炎患者特异性免疫治疗前后TGF-β、IL-10和IL-17的变化及和症状关系的研究

- 1 汕头市中心医院耳鼻咽喉科(广东汕头, 515031);
- 2 广东省人民医院广东省医学科学院耳鼻咽喉头颈外科
基金项目:
IQAP学术基金资助(No:200926)

详细信息

通讯作者: 邱前辉,E-mail:qiuqianhui@hotmail.com

中图分类号: R765.2

收稿日期: 2011-03-28

Role of TGF-β,IL-10 and IL-17 in allergic rhinitis patients with specific immunotherapy

- 1 Department of Otolaryngology, Shantou Central Hospital, Shantou, 515031, China;
- 2 Depart-ment of Otolaryngology-Head and Neck Surgery, Guangdong People's Hospital, Guangdong Academy of Medical Science

More Information

Corresponding author: QIU Qianhui, E-mail: qiuqianhui@hotmail.com

Received Date: 28 March 2011

摘要

摘要: 目的:研究变应性鼻炎(AR)患者特异性免疫治疗过程中血清TGF-β、IL-10和IL-17的变化情况及其与患者症状的相互关系。方法:应用酶联免疫吸附法测定48例AR患者血清TGF-β、IL-10和IL-17水平在特异性免疫治疗前及免疫治疗1、2年后的变化,对鼻部症状计分。并取35例健康者血清作为对照组。结果:①AR患者免疫治疗前血清TGF-β和IL-10水平均低于对照组(P<0.05)。免疫治疗2年后的血清TGF-β和IL-10水平均低于免疫治疗1年后,但高于免疫治疗前(均P<0.05);同时免疫治疗2年后低于对照组,两者差异有统计学意义(P<0.05)。②AR患者免疫治疗前血清IL-17水平高于对照组(P<0.05)。通过免疫治疗,IL-17水平逐渐下降,但治疗2年后仍高于对照组(P<0.05)。③AR患者治疗前与免疫治疗2年后血清中IL-10和TGF-β的水平分别与症状评分存在负相关,IL-17则与症状评分存在正相关(均P<0.05);AR患者免疫治疗1年后血清中IL-10、TGF-β及IL-17与症状评分均没有相关性(均P>0.05)。结论:在免疫治疗过程中,患者血清中IL-10、TGF-β呈波动性变化,先升高后降低,但始终高于免疫治疗前,而IL-17则呈持续性下降。IL-10、TGF-β及IL-17水平变化在免疫治疗2年后才与症状相关,提示特异性免疫治疗2年后,IL-10、TGF-β及IL-17可作为效果评估指标。
- 鼻炎,变应性 /
- 特异性免疫治疗 /
- TGF-β /
- IL-10 /
- IL-17
Abstract: Objective: To detect the level of TGF-β,IL-10 and IL-17 in the allergic rhinitis(AR) patients pre-and post-specific immunotherapy(SIT).Method: The level of TGF-β,IL-10 and IL-17 in serum of 48 AR patients were detected by enzyme-linked immunosorbent assay before SIT, and the nasal symptom score (NSS) was evaluated in the first and second year after SIT. At the same time, 35 healthy persons were made as normal.Result: ① The level of TGF-β and IL-10 in serum of AR patients were lower than that of normal group(P<0.05). The level of TGF-β and IL-10 in AR patients taken SIT for two years was lower than that of patients with one year SIT(P<0.05), but it was higher than that of patients pre-immunotherapy(P<0.05). However, The level of TGF-β and IL-10 in the group that taken SIT for two years was still lower than that of normal group(P<0.05). ② The level of IL-17 in serum of AR patients pre- immunotherapy was higher than that of normal group(P<0.05). The level of IL-17 continuously declined after taking SIT, However it was higher than that of normal group two years later(P<0.05). ③ In AR patients pre-immunotherapy and post- immunotherapy for 2 years, the level of IL-10 and TGF-β showed negative correlation with NSS respectively, the level of IL-17 was positive related to NSS respectively(P<0.05).But the level of IL-10, TGF-β and IL-17 showed no correlation with NSS respectively(P>0.05) when SIT was taken for one year.Conclusion: IL-10 and TGF-β were fluctuated in AR patients taking SIT, which arised first and then dropped. but the level of IL-10 and TGF-β was higher than that of pre- immunotherapy. However, the level of IL-17 continuously declined in the whole process. It showed that the level change of IL-10,TGF-[HK]
- rhinitis,allergic /
- specific immunotherapy /
- TGF-β /
- IL-10 /
- IL-17

HTML全文

参考文献(9)

[1]	中华医学耳鼻咽喉科学分会,中华耳鼻咽喉科杂志编辑委员会.变应性鼻炎诊治原则和推荐方案(2004年,兰州)[J].中华耳鼻咽喉科杂志,2005,40(3):166-167.
[2]	杨影,李春林,罗璝,等.Th17细胞在变应性鼻炎中的研究进展[J].临床耳鼻咽喉头颈外科杂志,2011,25(2):94-96.
[3]	PRIGIONE I, MORANDI F, TOSCA M A,et al. Interferon-gamma and IL-10 may protect from allergic polysensitization in children:preliminary evidence[J].Allergy, 2009, 65:740-742.
[4]	CHEUNG P F, WONG C K, LAM C W. Molecular mechanisms of cytokine and chemokine release from eosinophils activated by IL-17A, IL-17F, and IL-23:implication for Th17 lymphocytes-mediated allergic inflammation[J]. J Immunol, 2008, 180:5625-5635.
[5]	HE R,KIM H Y,YOON J,et al.Exaggerated IL-17 response to epicutaneous sensitization mediates airway inflammation in the absence of IL-4 and IL-13[J]. J Allergy Clin Immunol, 2009, 124:761-770, e761.
[6]	AL-RAMLI W, PRÉFONTAINE D, CHOUIALI F, et al. T(H)17-associated cytokines(IL-17A and IL-17F) in severe asthma[J].J Allergy Clin Immunol, 2009,123:1185-1187.
[7]	CIPRANDI G, DE AMICI M, MURDACA G, et al. Serum interleukin-17 levels are related to clinical severity in allergic rhinitis[J].Allergy, 2009, 64:1375-1378.
[8]	ALVAREZ-CUESTA E, BOUSQUET J, CANONICA G W, et al. Standards for practical allergen-specific immunotherapy[J]. Allergy, 2006, 61:1-20.
[9]	AJDUK J, MARINIC I, ABERLE N, et al. Effect of house dust mite immunotherapy on transforming growth factor beta1-producing T cells in asthmatic children[J]. Ann Allergy Asthma Immunol, 2008, 100:314-322.